Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus

Diabetes, Obesity & Metabolism
H QiuK Demissie


This was a retrospective cohort study of type 2 diabetes patients, to evaluate the association between initial metformin or sulphonylurea treatment and cancer incidence. Patients identified in the UK Clinical Practice Research Datalink (CPRD), previously General Practice Research Database, during 1995-2008 who were initially stabilized on OHA monotherapy, including metformin, sulphonylurea, thiazolidinediones (TZDs) or meglitinides, were included in the cohort. New diagnoses of cancer, including malignant solid tumours and haematological malignancies, occurring during the follow-up were identified from the cohort. Age-standardized incidence rates were estimated and compared between metformin and sulphonylurea exposure groups. The age standardized incidences of cancer were 7.5 and 8.5 per 1000 person-years for the metformin and sulphonylurea exposure groups, respectively. After adjusting for potential confounders, the hazard ratios (HR) for malignant solid tumours and haematological malignancies were 1.06 (95% CI: 0.98, 1.15) and 0.98 (95% CI: 0.67, 1.43) for sulphonylurea group as compared to the metformin group, respectively. For individual cancers, the HRs were 1.17 (95% CI: 0.95, 1.44), 1.04 (95% CI: 0.83, 1.31) and 0.88 (95...Continue Reading


Feb 1, 1992·Journal of Clinical Epidemiology·M Von KorffK Saunders
Feb 29, 1996·The New England Journal of Medicine·C J Bailey, R C Turner
Jun 27, 1998·British Journal of Clinical Pharmacology·L A García Rodríguez, S Pérez Gutthann
Sep 10, 1998·The New England Journal of Medicine·H JickL E Derby
Jun 10, 2000·British Journal of Clinical Pharmacology·R LawrensonR D Farmer
Nov 23, 2000·Lancet·H JickD A Drachman
Apr 20, 2001·JAMA : the Journal of the American Medical Association·T P van StaaC Cooper
Jun 9, 2001·BMJ : British Medical Journal·A HasseyA Wilson
Oct 14, 2004·Gastroenterology·Yu-Xiao YangJames D Lewis
Apr 26, 2005·BMJ : British Medical Journal·Josie M M EvansAndrew D Morris
May 12, 2005·British Journal of Cancer·R HuxleyM Woodward
Nov 17, 2005·Journal of the National Cancer Institute·Susanna C LarssonAlicja Wolk
Apr 3, 2007·International Journal of Cancer. Journal International Du Cancer·Susanna C LarssonAlicja Wolk
May 23, 2008·Gynecologic Oncology·Walter H GotliebIlan Bruchim
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sao JiralerspongAna M Gonzalez-Angulo
Nov 18, 2009·Diabetes Care·Gijs W D LandmanHenk J G Bilo
Jun 25, 2010·BMJ : British Medical Journal·Jennifer A HutcheonJames A Hanley
Oct 16, 2010·Cancer Prevention Research·Andrea DeCensiSara Gandini
Oct 27, 2010·Pharmacotherapy·M Shawn McFarland, Rebecca Cripps


Nov 19, 2014·Journal of the American Medical Directors Association·Barbara J Messinger-RapportJohn E Morley
May 28, 2014·Prostate Cancer and Prostatic Diseases·A M JoshuaM Pollak
Apr 29, 2015·Acta Diabetologica·Esther García-EsquinasMarina Pollán
Jan 7, 2016·Current Diabetes Reports·Asieh GolozarHsin-Chieh Yeh
Oct 21, 2015·Pharmacological Reports : PR·Anna TokajukHalina Car
Apr 10, 2013·Annales d'endocrinologie·Emmanuel Beck, André J Scheen
Feb 19, 2014·Diabetes, Obesity & Metabolism·S E Holden, C J Currie
Sep 26, 2015·Current Pharmacology Reports·Michael E GrossmannMargot P Cleary
May 26, 2017·Expert Opinion on Investigational Drugs·Rui GaoWei Xu
Apr 4, 2017·Pharmacoepidemiology and Drug Safety·Jin-Liern HongTil Stürmer
May 20, 2016·Investigative and Clinical Urology·Rashid Khalid Sayyid, Neil Eric Fleshner
Jul 28, 2017·Expert Opinion on Drug Safety·Marco TuccoriCorrado Blandizzi
Apr 6, 2019·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·Yongbo WangZhi-Jiang Zhang
Dec 14, 2019·Journal of Experimental & Clinical Cancer Research : CR·Muhamad Noor Alfarizal KamarudinIshwar Parhar
Nov 25, 2018·Diabetes, Obesity & Metabolism·Ruth L M Cordiner, Ewan R Pearson
May 30, 2020·Nature Reviews. Drug Discovery·Linda PartridgeBrian K Kennedy
Dec 13, 2019·Journal of Diabetes Research·Abraham Nigussie MekuriaKirubel Minsamo Mishore
Dec 30, 2016·International Journal of Epidemiology·Ruth E FarmerKrishnan Bhaskaran
Nov 27, 2014·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Anna H WuCheryl Vigen
Dec 11, 2019·Pathology, Research and Practice·Min DengHonghe Zhang
Mar 3, 2021·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Izabela Szymczak-PajorAgnieszka Śliwińska

Related Concepts

HB 699
Mammary Neoplasms, Human
Diabetes Mellitus, Non-Insulin-Dependent
Hypoglycemic Effect
Malignant Neoplasms
Malignant Neoplasm of Prostate
Retrospective Studies

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.